Top-Rated StocksTop-RatedNASDAQ:LRMR Larimar Therapeutics (LRMR) Stock Price, News & Analysis $2.89 +0.24 (+9.06%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Larimar Therapeutics Stock (NASDAQ:LRMR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Larimar Therapeutics alerts:Sign Up Key Stats Today's Range$2.52▼$2.8650-Day Range$1.71▼$3.1852-Week Range$1.61▼$11.20Volume3.09 million shsAverage Volume717,160 shsMarket Capitalization$185.04 millionP/E RatioN/ADividend YieldN/APrice Target$19.63Consensus RatingBuy Company OverviewLarimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Read More… Larimar Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreLRMR MarketRank™: Larimar Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 363rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingLarimar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLarimar Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Larimar Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Larimar Therapeutics are expected to decrease in the coming year, from ($1.15) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Larimar Therapeutics is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Larimar Therapeutics is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLarimar Therapeutics has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Larimar Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.14% of the float of Larimar Therapeutics has been sold short.Short Interest Ratio / Days to CoverLarimar Therapeutics has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Larimar Therapeutics has recently increased by 16.80%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLarimar Therapeutics does not currently pay a dividend.Dividend GrowthLarimar Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.14% of the float of Larimar Therapeutics has been sold short.Short Interest Ratio / Days to CoverLarimar Therapeutics has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Larimar Therapeutics has recently increased by 16.80%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.59 News SentimentLarimar Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Larimar Therapeutics this week, compared to 3 articles on an average week.Search Interest9 people have searched for LRMR on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Larimar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -30% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Larimar Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.50% of the stock of Larimar Therapeutics is held by insiders.Percentage Held by Institutions91.92% of the stock of Larimar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Larimar Therapeutics' insider trading history. Receive LRMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LRMR Stock News HeadlinesLarimar Therapeutics Reports First Quarter 2025 Financial ResultsApril 30 at 7:00 AM | globenewswire.comLarimar Therapeutics: Initiating Hold Rating With Upcoming CatalystsApril 5, 2025 | seekingalpha.comMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millions of years. And both grizzled oilmen and clean energy supporters love it: Energy Secretary Chris Wright called it "an awesome resource," while Warren Buffett, Jeff Bezos, Mark Zuckerberg, and Bill Gates are all directly invested.May 2, 2025 | Stansberry Research (Ad)Larimar Therapeutics Advances Nomlabofusp Program Amid Regulatory SupportMarch 27, 2025 | msn.comLarimar Therapeutics price target raised to $16 from $15 at H.C. WainwrightMarch 26, 2025 | markets.businessinsider.comLarimar Therapeutics price target lowered to $10 from $13 at BairdMarch 26, 2025 | markets.businessinsider.comWilliam Blair Sticks to Their Buy Rating for Larimar Therapeutics (LRMR)March 25, 2025 | markets.businessinsider.comLarimar Therapeutics Reports 2024 Financial Results and Development ProgressMarch 25, 2025 | tipranks.comSee More Headlines LRMR Stock Analysis - Frequently Asked Questions How have LRMR shares performed this year? Larimar Therapeutics' stock was trading at $3.87 at the beginning of the year. Since then, LRMR shares have decreased by 26.1% and is now trading at $2.86. View the best growth stocks for 2025 here. How were Larimar Therapeutics' earnings last quarter? Larimar Therapeutics, Inc. (NASDAQ:LRMR) announced its earnings results on Wednesday, April, 30th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.04. Who are Larimar Therapeutics' major shareholders? Top institutional shareholders of Larimar Therapeutics include Rhumbline Advisers (0.10%) and Alps Advisors Inc. (0.07%). Insiders that own company stock include James E Flynn, Michael Celano, Joseph Truitt and Frank E Thomas. View institutional ownership trends. How do I buy shares of Larimar Therapeutics? Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Larimar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Larimar Therapeutics investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings4/30/2025Today5/02/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LRMR CIK1374690 Weblarimartx.com Phone(844) 511-9056FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$19.63 High Stock Price Target$26.00 Low Stock Price Target$10.00 Potential Upside/Downside+586.2%Consensus RatingBuy Rating Score (0-4)3.10 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.87% Return on Assets-32.37% Debt Debt-to-Equity RatioN/A Current Ratio13.10 Quick Ratio13.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.86 per share Price / Book1.54Miscellaneous Outstanding Shares64,028,000Free Float61,574,000Market Cap$183.12 million OptionableOptionable Beta0.91 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:LRMR) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.